AEON Biopharma, Inc.
AMEX: AEON0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- New York Stock Exchange American
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Robert Bancroft
- Employees
- 5
- Headquarters
- Newport Beach, United States
- IPO year
- 2023
- Market cap
- $7.9M
- Website
- http://www.aeonbiopharma.com
Loading AEON…
Loading profile data…Frequently asked questions about AEON
What does AEON Biopharma, Inc. (AEON) do?
AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum toxin complex, which is being advanced for therapeutic use in conditions such as migraine, cervi...
Where does AEON trade?
AEON Biopharma, Inc. (AEON) trades on the New York Stock Exchange American.
What sector is AEON in?
AEON Biopharma, Inc. (AEON) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of AEON Biopharma, Inc.?
Robert Bancroft is the chief executive officer of AEON Biopharma, Inc. (AEON).
Where is AEON Biopharma, Inc. headquartered?
AEON Biopharma, Inc. is headquartered in United States.
Does AEON pay a dividend?
AEON Biopharma, Inc. (AEON) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did AEON go public?
AEON Biopharma, Inc. (AEON) completed its initial public offering in 2023.